BioAtla BCAB
NASDAQ BCAB
$3.18 +0.00 (+0.00%)
As of: Aug 21, 2026 · 3:59 PM EDT

BioAtla (BCAB) Net Equity Issued and Repurchased (2020 - 2026)

BioAtla (BCAB) posted quarterly Net Equity Issued and Repurchased of $400000.0 for Q1 2026, up 109.98% quarter-over-quarter from -$4.0 million in Q4 2021.

BioAtla (BCAB) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends

BioAtla's Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $400000.0 for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 BioAtla 5.41 Mn 5.41 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 400,000.00
Mar 31, 2026 400,000.00
Dec 31, 2021 -4.01 Mn
Dec 31, 2021 -4.01 Mn
Dec 31, 2020 68.18 Mn
Dec 31, 2020 68.18 Mn